Arvinas joins MJFF-backed PPMI study to support development of LRRK2 degrader ARV-102 for Parkinson’s

Arvinas, Inc.

Arvinas, Inc.

ARVN

0.00
  • Arvinas joined the Michael J. Fox Foundation-backed LITE and PPMI programs to support development of ARV-102, a brain-penetrant oral LRRK2 degrader.
  • No clinical results were presented; the collaborations are intended to inform future translational and clinical work, including target engagement assessment.
  • The move positions ARV-102 for Parkinson’s disease and progressive supranuclear palsy, aligning the program with shared biomarker data and biosamples.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.